Wells Fargo
DMAC icon

Wells Fargo’s DiaMedica Therapeutics DMAC Stock Holding History

Wells Fargo’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$260K Buy
36,928
+20,962
+131% +$129K ﹤0.01% 5032
2026
Q1 		$108K Sell
15,966
-24,663
-61% -$195K ﹤0.01% 5071
2025
Q4 		$323K Buy
40,629
+18,682
+85% +$140K ﹤0.01% 4787
2025
Q3 		$151K Buy
21,947
+7,295
+50% +$39.6K ﹤0.01% 5086
2025
Q2 		$57.1K Buy
14,652
+13,652
+1,365% +$53.2K ﹤0.01% 5465
2025
Q1 		$3.79K Buy
+1,000
New +$5.72K ﹤0.01% 6071
2024
Q2 		– Sell
-175
Closed -$485 – 7035
2024
Q1 		$485 Buy
175
+3
+2% +$9 ﹤0.01% 6285
2023
Q4 		$488 Buy
172
+9
+6% +$22 ﹤0.01% 6388
2023
Q3 		$421 Buy
163
+47
+41% +$151 ﹤0.01% 6401
2023
Q2 		$501 Buy
116
+4
+4% +$10 ﹤0.01% 6489
2023
Q1 		$171 Buy
112
+2
+2% +$3 ﹤0.01% 6817
2022
Q4 		$174 Buy
110
+3
+3% +$4 ﹤0.01% 6655
2022
Q3 		$0 Sell
107
-70
-40% -$109 ﹤0.01% 6777
2022
Q2 		$0 Buy
177
+14
+9% +$33 ﹤0.01% 6922
2022
Q1 		$0 Buy
163
+1
+0.6% +$3 ﹤0.01% 7190
2021
Q4 		$1K Buy
162
+47
+41% +$185 ﹤0.01% 6987
2021
Q3 		$0 Buy
115
+10
+10% +$38 ﹤0.01% 7040
2021
Q2 		$0 Sell
105
-1
-0.9% -$8 ﹤0.01% 6977
2021
Q1 		$1K Sell
106
-2,000
-95% -$18.7K ﹤0.01% 6701
2020
Q4 		$21K Buy
2,106
+31
+1% +$170 ﹤0.01% 5844
2020
Q3 		$8K Buy
2,075
+8
+0.4% +$42 ﹤0.01% 5930
2020
Q2 		$14K Buy
2,067
+2,000
+2,985% +$8.92K ﹤0.01% 5775
2020
Q1 		$0 Buy
+67
New +$277 ﹤0.01% 6300

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wells Fargo's DMAC Position: Q2 2026 in Review

Wells Fargo increased its DiaMedica Therapeutics (DMAC) stake by 131% in Q2 2026, buying an estimated $129K and bringing the position to 36,928 shares worth $260K. The position accounts for ﹤0.01% of the portfolio, ranked #5032.

Wells Fargo first reported a position in DMAC in Q1 2020 and has held it in 23 quarters since. The position peaked at $323K in Q4 2025. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Wells Fargo held 36,928 shares of DiaMedica Therapeutics worth $260K as of Q2 2026.
  • Wells Fargo bought 20,962 DiaMedica Therapeutics shares in Q2 2026, an estimated $129K.
  • DiaMedica Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5032 holding.
  • Wells Fargo first reported a position in DiaMedica Therapeutics in Q1 2020 and has held it in 23 quarters since.
  • Wells Fargo's DiaMedica Therapeutics position peaked at $323K in Q4 2025.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.